We also tested the potential effect of function blocking antibody against CXCL1 on invasion, since CXCL1 was also expressed from BMMSC-HSC-3 interaction and it has previously been demonstrated to be present in cancers including breast, lung, colorectal and prostate cancers either supporting or suppressing tumor progression [34–36]. This evidence concerns the gene CXCL1 and prostate carcinoma.